1. Home
  2. ZYME vs BTBT Comparison

ZYME vs BTBT Comparison

Compare ZYME & BTBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZYME
  • BTBT
  • Stock Information
  • Founded
  • ZYME 2003
  • BTBT 2015
  • Country
  • ZYME United States
  • BTBT United States
  • Employees
  • ZYME N/A
  • BTBT N/A
  • Industry
  • ZYME Biotechnology: Pharmaceutical Preparations
  • BTBT Finance: Consumer Services
  • Sector
  • ZYME Health Care
  • BTBT Finance
  • Exchange
  • ZYME Nasdaq
  • BTBT Nasdaq
  • Market Cap
  • ZYME 968.5M
  • BTBT 1.1B
  • IPO Year
  • ZYME 2017
  • BTBT 2018
  • Fundamental
  • Price
  • ZYME $12.43
  • BTBT $3.37
  • Analyst Decision
  • ZYME Buy
  • BTBT Strong Buy
  • Analyst Count
  • ZYME 7
  • BTBT 3
  • Target Price
  • ZYME $19.50
  • BTBT $6.33
  • AVG Volume (30 Days)
  • ZYME 409.0K
  • BTBT 44.5M
  • Earning Date
  • ZYME 08-07-2025
  • BTBT 08-18-2025
  • Dividend Yield
  • ZYME N/A
  • BTBT N/A
  • EPS Growth
  • ZYME N/A
  • BTBT N/A
  • EPS
  • ZYME N/A
  • BTBT N/A
  • Revenue
  • ZYME $93,384,000.00
  • BTBT $102,037,923.00
  • Revenue This Year
  • ZYME $44.71
  • BTBT $20.87
  • Revenue Next Year
  • ZYME $34.57
  • BTBT $38.28
  • P/E Ratio
  • ZYME N/A
  • BTBT N/A
  • Revenue Growth
  • ZYME 85.05
  • BTBT 52.44
  • 52 Week Low
  • ZYME $9.03
  • BTBT $1.69
  • 52 Week High
  • ZYME $17.70
  • BTBT $5.74
  • Technical
  • Relative Strength Index (RSI)
  • ZYME 40.44
  • BTBT 51.88
  • Support Level
  • ZYME $12.26
  • BTBT $2.66
  • Resistance Level
  • ZYME $13.80
  • BTBT $3.04
  • Average True Range (ATR)
  • ZYME 0.62
  • BTBT 0.29
  • MACD
  • ZYME -0.21
  • BTBT -0.05
  • Stochastic Oscillator
  • ZYME 10.19
  • BTBT 25.67

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

About BTBT Bit Digital Inc.

Bit Digital Inc is engaged in the Bitcoin mining business, Ethereum staking activities and specialized cloud-infrastructure services for artificial intelligence applications through its wholly owned subsidiaries. Its mining platform operates with the primary intent of accumulating bitcoin which may sell for fiat currency from time to time depending on market conditions. The Company has four reportable segments: digital asset mining, cloud services, colocation services, and ETH Staking. It generates majority of its revenue from digital asset mining.

Share on Social Networks: